drugset / Trial / NCT04455243

Inflammatory Regulation Effect of NAC on COVID-19 Treatment

NCT04455243

Phase 3 Unknown 1180 enrolled King Saud University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Study times to evaluate the efficacy of N-Acetylcysteine therapy in the management of adult admitted patients with COVID-19.

Timeline

Start
2020-08-01
Primary completion
2021-08-30
Completion
2021-08-30

Drugs

EvaluationDrugModalityDoseRoute
Subject N-acetylcysteine Small molecule 150 mg/kg Oral

Indications